University of Maryland, Baltimore

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Maryland, Baltimore sits in the top decile of US sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count).

560 total trials 103 currently recruiting 332 completed early-phase tilt top decile by trial count

University of Maryland, Baltimore: 560 sponsored US clinical trials, 103 recruiting.

University of Maryland, Baltimore sponsors 560 registered US clinical trials on ClinicalTrials.gov, 103 of them currently recruiting, and 332 completed. 77 of these trials are in Phase 3-4 (later-stage) and 161 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 14 trials.

Top-decile sponsor footprint

University of Maryland, Baltimore ranks in the top decile of sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 42/100

332 of 410 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

560 total, page 9 of 12

COMPLETED NA

Exercise Trial in Chronic Kidney Disease

NCT01462097

COMPLETED NA

Gingival Augmentation Around Implants During Maintenance

NCT02904551

TERMINATED Phase 4

Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study

NCT01452152

COMPLETED NA

Intervention to Enhance Lateral Balance Function and Prevent Falls in Aging

NCT01370174

COMPLETED NA

MobileMedMinder: A Networked Aide for Medication Compliances

NCT01597583

TERMINATED NA

Effects of Nocturnal Nasal Oxygen on Biomarkers in Sleep Apnea Patients With Heart Failure

NCT01431157

COMPLETED

MRI for Eval Tumor & Node Response & Normal Tissue Function to Concurrent Chemo & Radiation Therapy in H&N Cancer (GCC1043)

NCT01768442

COMPLETED Phase 2

HEART to HAART: Smartphone Intervention to Improve HAART Adherence for Drug Users

NCT01413529

COMPLETED NA

Enhanced Room Cleaning in Intensive Care Units to Reduce Gown and Glove Contamination With Multi-drug-resistant Bacteria

NCT01481935

COMPLETED

Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease

NCT02619552

TERMINATED Phase 4

Duloxetine for the Treatment of Chronic Pelvic Pain

NCT01451606

COMPLETED Phase 1

Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP

NCT01531530

COMPLETED

Intracellular Tight Junction Permeability in Schizophrenia: Focus on Zonulin

NCT01558570

COMPLETED NA

Adjunctive Minocycline in Clozapine Treated Schizophrenia Patients

NCT01433055

COMPLETED NA

Development of a Rehabilitation Strengthening and Mobility Program for Ventilator Dependent Older Patients

NCT03195127

COMPLETED NA

1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma

NCT01541644

COMPLETED NA

RCT Determining Best Treatment for Geriatric Acetabular Fractures

NCT03419182

COMPLETED

Safe Kidney Care Cohort Study

NCT01407367

COMPLETED NA

Comparison of Lokomat and Aquatic Exercise for Individuals With Chronic Incomplete Spinal Cord Injury

NCT01407354

TERMINATED NA

Smart Glucose Meter Project

NCT01341587

COMPLETED Phase 4

Cimetidine Biowaivers

NCT01256879

COMPLETED NA

Telehome Monitoring for Chronic Disease Management

NCT02035566

COMPLETED NA

Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia

NCT01338298

TERMINATED NA

Effectiveness of SMS (Short Message Service) Text Messaging in Increasing Adherence to Gardasil

NCT01276184

COMPLETED

Brain Circuits in Schizophrenia and Smoking

NCT01425684

COMPLETED NA

Increasing Motivation for Antiretroviral Therapy Initiation: A Pilot Intervention

NCT02055417

COMPLETED

Benefits of Universal Glove and Gowning

NCT01318213

COMPLETED

Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States

NCT01425671

COMPLETED NA

Nicotinic Modulation of the Default Network

NCT01223404

COMPLETED Early Phase 1

Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus

NCT00607646

TERMINATED Phase 2

Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery

NCT01234532

COMPLETED NA

Face Transplantation

NCT01140087

COMPLETED NA

R5 Integrase Study in HIV-1 Naive Patients

NCT01204905

COMPLETED NA

Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Miral Operation

NCT01246947

COMPLETED NA

Salsalate for Insulin Resistance in Schizophrenia

NCT01182727

COMPLETED NA

Clopidogrel Pharmacogenetics (PGX) Bench to Bedside

NCT01341600

COMPLETED NA

Trial of Lithium Carbonate for Treatment of Osteoporosis-pseudoglioma Syndrome

NCT01108068

COMPLETED

Long-term Follow-up of Spare the Nephron (STN) Patients

NCT01126333

COMPLETED Phase 2

Effects of Galantamine on Cognition

NCT01100775

COMPLETED Phase 1

Safety and Immunogenicity of CVD 1902 Oral Attenuated Vaccine to Prevent S. Paratyphi A Infection

NCT01129453

TERMINATED Phase 1

Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies

NCT01110226

COMPLETED

Chitosan Chewing Gum Study in Dialysis Patients

NCT01770470

COMPLETED

Imaging of Traumatic Brain Injury

NCT01196299

COMPLETED NA

Imaging With a Radio Tracer to Guide VT Ablations

NCT01250912

TERMINATED Phase 1

GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers

NCT01118975

COMPLETED Phase 2

Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia

NCT01012167

COMPLETED NA

Transcranial Direct Current Stimulation (tDCS) and Parkinson's Disease

NCT01100762

COMPLETED NA

Telephone Based Cognitive Behavioral Therapy for HIV Related Depression

NCT01055158

COMPLETED Phase 2

Oxytocin and Social Cognition in Schizophrenia

NCT00884897

COMPLETED Phase 4

Safety Study of Seasonal Influenza Vaccine by Jet Injection

NCT00987350

← Previous Page 9 of 12 Next →

Phase Distribution

PhaseTrial count
Phase 1 82
Phase 2 79
Phase 3 10
Phase 4 67

What is open in the University of Maryland, Baltimore pipeline

103 recruiting of 560 indexed (18% open); 332 completed (59%).

Phase mix: 77 late (III/IV) vs 161 early (I/II) (early-phase heavy).

Top condition: Schizophrenia (14 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Maryland, Baltimore: open-pipeline peers nationwide

Peers matched on 560 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 5%10%15%20%25% Total trials Recruiting share University of Maryland, BaltimoreAmgenMerck Sharp & DohmeVirginia Commonwealth UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Abramson Cancer Center at Penn MedicineHenry Ford Health SystemNew York Institute of TechnologyUniversity of California, San Diego
University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 560 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this University of Maryland, Baltimore page

560 registered trials is a research-attention snapshot, not an endorsement of University of Maryland, Baltimore or any single study.

  • 103 of University of Maryland, Baltimore's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Schizophrenia is the condition University of Maryland, Baltimore studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Maryland, Baltimore pipeline card: 560 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.